Valeo Pharma Inc
Valeo Pharma Inc. operates as a pharmaceutical company focused on licensing, acquiring, and commercializing drugs. The company provides commercialized pharmaceutical products in Canada, with a focus on respiratory/allergy, ophthalmology, and specialty therapeutic areas. It licenses and acquires Canadian rights to commercial-stage and proprietary drugs, managing registration and commercialization … Read more
Valeo Pharma Inc (VPHIF) - Total Assets
Latest total assets as of July 2024: $32.20 Million USD
Based on the latest financial reports, Valeo Pharma Inc (VPHIF) holds total assets worth $32.20 Million USD as of July 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Valeo Pharma Inc - Total Assets Trend (2016–2023)
This chart illustrates how Valeo Pharma Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Valeo Pharma Inc - Asset Composition Analysis
Current Asset Composition (October 2023)
Valeo Pharma Inc's total assets of $32.20 Million consist of 61.3% current assets and 38.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 18.2% |
| Accounts Receivable | $6.57 Million | 15.9% |
| Inventory | $10.25 Million | 24.9% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $11.70 Million | 28.4% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2023)
This chart illustrates how Valeo Pharma Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Valeo Pharma Inc's current assets represent 61.3% of total assets in 2023, a decrease from 79.8% in 2016.
- Cash Position: Cash and equivalents constituted 18.2% of total assets in 2023, up from 4.8% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 28.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is intangible assets at 28.4% of total assets.
Valeo Pharma Inc Competitors by Total Assets
Key competitors of Valeo Pharma Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biostar Pharmaceuticals Inc
PINK:BSPM
|
USA | $41.43 Million |
|
High Sierra Technologies Inc
PINK:HSTI
|
USA | $10.70K |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
Valeo Pharma Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Valeo Pharma Inc generates 1.31x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Valeo Pharma Inc is currently not profitable relative to its asset base.
Valeo Pharma Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.27 | 1.77 | 0.37 |
| Quick Ratio | 0.20 | 0.98 | 0.24 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-50.85 Million | $ 12.52 Million | $ -2.83 Million |
Valeo Pharma Inc - Advanced Valuation Insights
This section examines the relationship between Valeo Pharma Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 66.75 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -29.3% |
| Total Assets | $41.21 Million |
| Market Capitalization | $9.87K USD |
Valuation Analysis
Below Book Valuation: The market values Valeo Pharma Inc's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Valeo Pharma Inc's assets decreased by 29.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Valeo Pharma Inc (2016–2023)
The table below shows the annual total assets of Valeo Pharma Inc from 2016 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-10-31 | $41.21 Million | -29.28% |
| 2022-10-31 | $58.27 Million | +177.06% |
| 2021-10-31 | $21.03 Million | +91.83% |
| 2020-10-31 | $10.96 Million | +88.79% |
| 2019-10-31 | $5.81 Million | +71.53% |
| 2018-10-31 | $3.39 Million | -0.42% |
| 2017-10-31 | $3.40 Million | -20.20% |
| 2016-10-31 | $4.26 Million | -- |